On the Frontline: Immunotherapeutic Approaches in Advanced NSCLC

Program Overview

Immunotherapy has rapidly changed the landscape of therapeutic options for patients with metastatic NSCLC. Led by an expert panel, this activity will equip clinicians with the tools to identify patients eligible for frontline checkpoint inhibitor monotherapy, privileged insights into optimal therapeutic selection based on the latest clinical trial data, and strategies for optimal management of adverse events. A patient panelist shares his treatment journey, offering a novel perspective for healthcare professionals.

Credit Expired

0.75 CE Credit(s)

Expires: October 28, 2022

Target Audience

This activity is intended for medical oncologists, pathologists, pulmonologists, and other clinicians engaged in the care of patients with non-small cell lung cancer (NSCLC).

Educational Objectives

Upon completion of this activity, participants should be better able to:

Use biomarker testing to inform frontline treatment decisions in patients with advanced non-small cell lung cancer (NSCLC)
Assess current data on immune checkpoint inhibitors for the frontline treatment of advanced NSCLC
Identify patients with advanced NSCLC in whom frontline treatment with an immune checkpoint inhibitor may be beneficial
Recognize potential immunotherapy-related adverse events in patients with advanced NSCLC who are undergoing treatment with an immune checkpoint inhibitor in the frontline setting

Activity Faculty

Roy S. Herbst, MD, PhD

Ensign Professor, Medicine (Medical Oncology) and Professor, Pharmacology

Chief, Medical Oncology

Yale Cancer Center and Smilow Cancer Hospital

Associate Cancer Center Director, Translational Research

Yale Cancer Center

New Haven, CT 

Sarah B. Goldberg, MD, MPH

Associate Professor, Internal Medicine (Medical Oncology)

Yale Cancer Center 

New Haven, CT

Prof. Aleš Ryška, MD, PhD

Head, Fingerland Department of Pathology

Charles University, Medical Faculty

Hradec Králové, Czech Republic

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 